Q4 2024 · 13F-HR
Casdin Capital, LLCholdings as filed
Filed 2025-02-14 · accession 0000919574-25-001518
$1.50B
Reported value
39
Positions
2024-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 81663L200 | WGS | GENEDX HOLDINGS CORP | $269.6M | 17.9% | 3,507,164 | Common | SOLE |
| 09062W204 | BLFS | BIOLIFE SOLUTIONS INC | $226.0M | 15.0% | 8,707,165 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $161.8M | 10.8% | 3,699,283 | Common | SOLE |
| 803607100 | SRPT | SAREPTA THERAPEUTICS INC | $130.5M | 8.69% | 1,073,500 | Common | SOLE |
| 34385P108 | LAB | STANDARD BIOTOOLS INC | $124.7M | 8.30% | 71,254,677 | Common | SOLE |
| 452327109 | ILMN | ILLUMINA INC | $100.2M | 6.67% | 750,000 | Common | SOLE |
| 05370A108 | RNAGBP | AVIDITY BIOSCIENCES INC | $59.5M | 3.96% | 2,045,000 | Common | SOLE |
| 192005106 | CDXS | CODEXIS INC | $38.6M | 2.57% | 8,100,000 | Common | SOLE |
| 75943R102 | RLAY | RELAY THERAPEUTICS INC | $36.9M | 2.45% | 8,948,574 | Common | SOLE |
| 30063P105 | EXK | EXACT SCIENCES CORP | $36.5M | 2.43% | 650,000 | Common | SOLE |
| 02043Q107 | ALNY | ALNYLAM PHARMACEUTICALS INC | $32.9M | 2.19% | 140,000 | Common | SOLE |
| 07373V105 | BEAM | BEAM THERAPEUTICS INC | $31.0M | 2.06% | 1,250,000 | Common | SOLE |
| 64135M105 | NGNE | NEUROGENE INC | $29.6M | 1.97% | 1,295,361 | Common | SOLE |
| 09627Y109 | 2655787D | BLUEPRINT MEDICINES CORP | $28.5M | 1.89% | 326,378 | Common | SOLE |
| 45826J105 | NTLA | INTELLIA THERAPEUTICS INC | $23.3M | 1.55% | 2,000,000 | Common | SOLE |
| 92539P101 | — | VERVE THERAPEUTICS INC | $22.5M | 1.50% | 3,995,571 | Common | SOLE |
| 24823R105 | DNLI | DENALI THERAPEUTICS INC | $20.2M | 1.34% | 990,000 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $19.0M | 1.26% | 700,000 | Common | SOLE |
| 81734D104 | SEPN | SEPTERNA INC | $12.7M | 0.84% | 553,268 | Common | SOLE |
| 92337F107 | VCYT | VERACYTE INC | $10.9M | 0.73% | 276,308 | Common | SOLE |
| 40131M109 | GH | GUARDANT HEALTH INC | $10.7M | 0.71% | 350,000 | Common | SOLE |
| 87990A106 | TNYA | TENAYA THERAPEUTICS INC | $9.6M | 0.64% | 6,732,971 | Common | SOLE |
| 00847X104 | AGIO | AGIOS PHARMACEUTICALS INC | $8.2M | 0.55% | 250,000 | Common | SOLE |
| 60770K107 | MRNA | MODERNA INC | $7.3M | 0.48% | 175,000 | Common | SOLE |
| 60770K107 | MRNA | MODERNA INC | $7.3M | 0.48% | 175,000 | CALL | SOLE |
| 35104E100 | FDMT | 4D MOLECULAR THERAPEUTICS IN | $6.4M | 0.43% | 1,150,000 | Common | SOLE |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS INC | $6.3M | 0.42% | 475,000 | Common | SOLE |
| 901384107 | TSVT* | 2SEVENTY BIO INC | $5.9M | 0.39% | 2,000,000 | Common | SOLE |
| 15673T100 | IPSC | CENTURY THERAPEUTICS INC | $5.2M | 0.35% | 5,190,506 | Common | SOLE |
| 34965K107 | FTRE | FORTREA HLDGS INC | $5.1M | 0.34% | 275,000 | Common | SOLE |
| 21217B100 | CTNM | CONTINEUM THERAPEUTICS INC | $4.3M | 0.29% | 296,666 | Common | SOLE |
| 87583X109 | TNGX | TANGO THERAPEUTICS INC | $3.7M | 0.24% | 1,188,349 | Common | SOLE |
| 00091E109 | ABSI | ABSCI CORPORATION | $2.5M | 0.17% | 973,260 | Common | SOLE |
| 69404D108 | PACB | PACIFIC BIOSCIENCES CALIF IN | $1.9M | 0.13% | 1,035,859 | Common | SOLE |
| 75629V104 | RXRX | RECURSION PHARMACEUTICALS IN | $1.1M | 0.07% | 165,323 | Common | SOLE |
| 74168J101 | PRME | PRIME MEDICINE INC | $1.1M | 0.07% | 367,175 | Common | SOLE |
| 61225M102 | GLUE | MONTE ROSA THERAPEUTICS INC | $596,937 | 0.04% | 86,014 | Common | SOLE |
| 37611X209 | DNA | GINKGO BIOWORKS HOLDINGS INC | $358,361 | 0.02% | 36,493 | Common | SOLE |
| 50107A104 | KRON1USD | KRONOS BIO INC | $117,647 | 0.01% | 123,839 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.